Five Years on Teduglutide: When Does a Response Become a Dependency?
A single patient, five years into a genuine teduglutide response, raising the question himself: does he actually still need this, or has the drug just been quietly propping up a plateau nobody has tested in years?
Walter K., a 67-year-old retired postal carrier, spent thirty-four years walking the same route before an acute mesenteric arterial occlusion in his late fifties took most of his small bowel in an emergency resection, leaving him with roughly 100 centimeters of jejunum and a permanent ileostomy. He has been on teduglutide for five years, started after his parenteral-support requirement plateaued at 9 liters weekly and showed no further improvement on nutritional optimization alone. The response was real and it held: PS volume dropped to 4 liters, three nights a week, within the first eighteen months, and has sat there, unchanged, for the past three and a half years. He now spends most mornings at the community garden plot he and his late wife started together, and raised the question himself at this visit — not because anything is wrong, but because his grandson recently asked him how long he’d be “on the shot,” and he realized he didn’t actually know the answer.
That plateau is exactly what makes the decision genuinely uncertain rather than routine. A nine-year discontinuation follow-up (Zaczek et al.) found that among patients with PN-dependent short bowel syndrome who stopped teduglutide, weekly PN requirements stayed roughly stable for about four years after discontinuation and then climbed in the majority of patients between years five and nine, with over half the cohort needing at least a one-fifth increase above their pre-treatment baseline by the nine-year mark — a real, delayed rebound, not an immediate one, which means a short discontinuation trial wouldn’t necessarily catch it even if it happens. Walter’s own three and a half years of stability at a fixed dose cuts against a simple reading of that data in one direction: has his gut finished adapting and now needs the drug only to hold that gain, in which case stopping risks exactly the rebound the cohort describes — or has his intestine kept adapting quietly underneath a dose that was never re-tested, in which case the plateau reflects an untested ceiling rather than a durable floor. Nobody in the room can currently tell those two possibilities apart from his chart alone.
Intestinal failure clinic, five-year review
My instinct is to leave this alone. He is a real responder, stable for three and a half years, and the one dataset that actually followed patients after stopping this drug found the rebound doesn’t even show up until year five — by year nine, more than half the cohort needed a meaningful increase above their own pre-treatment baseline. That’s not a soft signal. If we stop now and he’s in that majority, we’re not just losing three years of gain, we’re potentially losing ground relative to where he started.
I want to be honest that "leave it alone" is also the easier answer for me to give — it doesn’t require a monitoring plan or a hard conversation if something changes. That’s not a reason it’s wrong, but it’s worth naming.
I hear the rebound data, but I keep coming back to the fact that he’s 67 and this isn’t the only thing that could interrupt his regimen in the next several years — a formulary change, a supply disruption, a hospitalization that gets his home regimen tangled up. If that happens without any prior data on how he tolerates a break, we’re managing a crisis blind. A planned, monitored trial now, while he’s stable and we can watch him closely, tells us something real about his own resilience that we’d otherwise only learn the hard way.
I’m not proposing we ignore the cohort data — I’m proposing we’d rather generate his own data under controlled conditions than have his first discontinuation experience be an accident.
Both of you are reasoning from the same nine-year cohort, and I want to flag what that cohort actually was: patients who started teduglutide between 2009 and 2013, an earlier treatment era, not necessarily five-year continuous responders monitored the way Walter has been. A population average from a somewhat different group is a reasonable prior, not a prediction about him specifically.
What I’d actually want before deciding either way is something neither of the other two positions used: has his PS requirement genuinely been flat at a fixed dose, or has there been any slow drift downward that got absorbed into "stable" because nobody was tracking it month to month? If the trend line is truly flat, that argues his adaptation may have already run its course, and the rebound risk applies more directly. If there’s a quiet downward drift underneath the plateau, that’s evidence he might tolerate a taper better than the cohort average suggests. We don’t currently have that granularity in his chart, and I think we should get it before either committing to indefinite therapy or scheduling a discontinuation trial.
Agreed: pull his last three years of monthly PS-volume records for a genuine trend review before the next visit, rather than deciding from the "stable x3.5 years" summary alone. Teduglutide continues unchanged in the meantime.
Not agreed, and explicitly left open pending that data: if the trend is genuinely flat, whether that argues for continuing indefinitely (the nutrition-support physician’s reading) or for attempting a monitored taper now while he is healthy enough to tolerate one (the primary care physician’s reading). Both said they would revisit their own position once the actual trend data is in hand, rather than defend it on the current summary alone.